-
Santarus Reports Fourth Quarter and Full Year 2010 Financial Results
Thursday, March 3, 2011 - 5:12pm | 117Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter and full year ended December 31, 2010. Key financial results for the 2010 fourth quarter: Total revenues of $25.9 million. Net loss of $2.1 million, or $0.03 per...
-
Somaxon Pharma Misses EPs Estimates: ($0.42) Vs. ($0.40) (SOMX)
Thursday, March 3, 2011 - 5:10pm | 669Somaxon Pharmaceuticals (NASDAQ: SOMX) today announced financial results for the full year and fourth quarter ended December 31, 2010. “During 2010, we achieved our key corporate objectives that allowed us to successfully transition from a development stage organization to a commercial specialty...
-
Slow Grind Squeezes Shorts 03-03-2011
Thursday, March 3, 2011 - 4:34pm | 871Cusick's Corner Dollar weak, Oil stable (for now) and the rest of the world readying to fight inflation -- the market is up across the board. The data both domestically and internationally is coming in better than expected, ramping up expectations of further upticks in employment and economic...
-
FDA Action Affects Products Marketed by Hi-Tech Pharmacal's ECR Pharmaceuticals Subsidiary
Thursday, March 3, 2011 - 10:28am | 84Hi-Tech Pharmacal Co. (NASDAQ: HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration has indicated, in its MedWatch publication, that the Agency intends to remove approximately 500 currently marketed cough/cold and allergy related products. Three of...
-
Goldman Sachs Suggests Buying Calls on Bristol-Myers Squibb (BMY)
Thursday, March 3, 2011 - 10:11am | 180Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on Bristol-Myers Squibb (NYSE: BMY) ahead of several data releases. Goldman Sachs Pharma analyst, Jami Rubin, sees 6-8% upside potential for BMY shares, driven by catalysts...
-
Targacept Announces Termination of Strategic Alliance Agreement with GlaxoSmithKline
Thursday, March 3, 2011 - 9:56am | 138Targacept, Inc. (NASDAQ: TRGT) today announced the termination of its strategic alliance agreement with GlaxoSmithKline (NYSE: GSK), effective in May 2011. Targacept and GSK entered into the agreement in July 2007 with the goal to discover, develop and market novel...
-
Charles River to Supply Pfizer's Genetically Modified Research Models
Thursday, March 3, 2011 - 9:35am | 92Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a marketing and distribution agreement with Pfizer Inc. (NYSE: PFE) to provide certain Pfizer-developed genetically modified research models to the global biomedical research community....
-
Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study
Thursday, March 3, 2011 - 9:04am | 170Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON, an investigational type 2 diabetes therapy, to daily Victoza. Both drugs...
-
Goldman Removes Allergan From Conviction Buy (AGN)
Thursday, March 3, 2011 - 8:52am | 181Goldman Sachs is removing Allergan, Inc. (NYSE: AGN) from its Conviction Buy List, but is still keeping shares rated at Buy. It has a $84 price target on shares. In a note to investors, Goldman writes, "We are removing AGN from the Conviction Buy List and replacing it with...
-
Five Trade Ideas for Thursday, March 03
Wednesday, March 2, 2011 - 7:48pm | 2572( click to enlarge ) Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) is setting up for a nice upside move and I'm going to be there when it occurs. The stock traded higher again on Wednesday as the stock ended the day near highs. The strength at the end of the day tells us to expect continued buying...
-
DURECT Corporation Reports Q4 EPS of $(0.06)
Wednesday, March 2, 2011 - 5:10pm | 64DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2010. Total revenues were $8.5 million for the three months ended December 31, 2010, up from $4.9 million for the three months ended December 31, 2009. Net loss for the three months ended...
-
Options Brief: Repros Therapeutics (RPRX)
Wednesday, March 2, 2011 - 12:07pm | 72Shares of Repros Therapeutics (NASDAQ: RPRX) are higher on the session by 9.36%, trading at $6.33. Overall call volume is now running at 10.49x the daily average, with 66% of all calls traded being purchases on the offer. 1,427 contracts have traded on the session so far. Repros Therapeutics Inc....
-
NASDAQ Stocks Hitting 52-Week Highs (PEET, RPRX, FEIC, ALXN)
Wednesday, March 2, 2011 - 11:07am | 144Peet's Coffee & Tea Inc (NASDAQ: PEET) shares reached $47.25 to create a new 52-week high, before falling to $46.98, representing a 9.59% gain. Analysts at Janney Capital upgraded PEET from “neutral” to “buy.” Repros Therapeutics Inc (NASDAQ: RPRX) shares jumped 8.81% to touch a new 52-week...
-
Citigroup On Watson Pharmaceuticals Following Healthcare Conference
Wednesday, March 2, 2011 - 10:27am | 134Citigroup has published a research report on Watson Pharmaceuticals (NYSE: WPI) after the company's participation in Citi's Healthcare conference. In the report, Citigroup writes "Paul Bisaro, WPI's President & CEO reiterated WPI's 2011 diluted EPS target of $3.85 to $4.15 and revenue of $4.2B...
-
Fast Money Pops & Drops, March 1st (CCL, BYD, LO, EMN, VVUS)
Tuesday, March 1, 2011 - 9:41pm | 277On CNBC's Fast Money Pops & Drops, Tim Seymour said that COO of Carnival Corporation (NYSE: CCL) sold 180,000 shares in late February. He thinks that it would be smart to stay away from this stock. Carnival Corporation (CCL) fell 6.07% today, and closed at $40.08. Pete Najarian commented on...